Financial News

Shanghai ImmuneOnco Raises $89 Million for Cancer Immunotherapies

Shanghai ImmuneOnco Biopharma completed an $89 million Series C funding led by Guangdong 's Greater Homeland Bay Area Investments and Lilly Asia Ventures. Founded in 2015, ImmuneOnco has established discovery platforms that exploit two types of innate immune cells: macrophages and natural killer (NK) cells. The company has been approved to start two clinical trials: IMM01, an anti-CD47 fusion protein, was approved in China , and IMM0306, a bispecific antibody targeting CD47 and CD20, was approved in the US . More details.... Share this with colleagues: // //
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.

Use the myMotherLode.com Keyword Search to go straight to a specific page

Popular Pages

  • Local News
  • US News
  • Weather
  • State News
  • Events
  • Traffic
  • Sports
  • Dining Guide
  • Real Estate
  • Classifieds
  • Financial News
  • Fire Info
Feedback